Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

A pill that can shrink and potentially eliminate pancreas tumours is being hailed as the biggest breakthrough treatment for the cancer in decades.

In one in 12 of the patients given the drug, daraxonrasib, during a trial, the cancer became undetectable, and the tumours stopped growing in almost all of the 61 patients. The trial participants had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

Though doctors have said the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay, they have said it is encouraging news because it appears it will offer patients more time, even if it does not cause full remission.

Half of all people diagnosed with pancreatic cancer die within three months, and only about 3% of patients survive for five years when the disease spreads to other organs. It has the lowest survival rate of all common cancers in the UK and has a similarly poor prognosis globally.

Patients were followed for a year and a half during the trial on average and some did not see the cancer return during this period. Longer studies will be conducted to see if any of the cancers can be put into remission. During the trial, tumours stopped growing in 90% of patients, just over 60% of patients had their tumours shrink or disappear, and for about 8% of patients tumours became undetectable on CT scans.

A year after starting treatment, 76.6% of patients were alive; usually 40-45% of patients given chemotherapy alone survive a year.

Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the findings, said "this is the closest to cure", adding that he had never seen so many tumours disappear in patients whose cancer had spread.

He presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. "We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival," he said.

"The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that's closest to complete remission … it's incredible."

Daraxonrasib is a KRAS inhibitor treatment, which works by locking on to and shutting off certain mutations found in most pancreatic cancers. These mutations drive tumour growth.

There are hopes the treatment could work for dozens of other cancers because they can have similar mutations.

Michelle Mitchell, Cancer Research UK's chief executive, said more research was needed, but added: "This is the biggest leap forward we've seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers.

"These results raise the exciting possibility that this breakthrough could eventually pave the way for treating other cancers that carry Kras gene mutations. More trials are now needed before this treatment can be assessed for use on the NHS and despite this advance, pancreatic cancer survival is still very low."

Original source Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

Back to home